NEW YORK (AP) – The next is an inventory of preliminary public choices deliberate for subsequent week. Sources embrace the Renaissance Capital IPO ETF supervisor and SEC filings.
Week of February 1
Atotech – Berlin, Germany, 34.1 million shares, priced from $ 19 to $ 22, managed by Citi / Credit score Suisse. NYSE ATC proposed. Enterprise: Carlye-backed specialty chemical compounds firm spun off from Whole.
Evaxion Biotech – Copenhagen, Denmark, 2.eight million shares, priced $ 10- $ 12, managed by Oppenheimer & Co / Ladenburg Thalmann. Nasdaq’s proposed image EVAX. Enterprise: Danish part half biotechnology utilizing AI to develop immunoocological therapies.
Landos Biopharma – Blacksburg, Va., 6.three million shares, priced $ 15 to $ 17, managed by JP Morgan Stanley / Jefferies. Nasdaq’s proposed image LABP. Enterprise: Part 2 biotechnology creating oral small molecule therapies for autoimmune ailments.
Depot Mortgage – Foothill Ranch, California, 15 million shares, priced $ 19 to $ 21, managed by Goldman Sachs / BofA Securities. NYSE LDI proposed. Enterprise: Non-bank lender targeted on mortgages and unsecured private loans.
ON24 – San Francisco, eight.6 million shares, priced $ 45- $ 50, managed by Goldman Sachs / JP Morgan. NYSE ONTF proposed. Enterprise – Offers cloud-based webcasting and digital communications companies.
Sana Biotechnology – Seattle, 15 million shares, priced $ 20 to $ 22, managed by Morgan Stanley / Goldman Sachs. Nasdaq’s proposed image SANA. Enterprise: Preclinical biotechnology that develops cell therapies designed for a number of indications.
